source
- Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitisEvommune reported that its experimental small-molecule antagonist of the MRGPRX2 receptor did not meet its primary endpoints in a Phase 2b study in patients with atopic dermatitis. The study, cond…
- FDA makes acting CBER and CDER heads permanent, signaling leadership continuityFDA promoted Michael Davis and Karim Mikhail from acting to permanent heads of the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). The ap…